Speaker articles

Take a look at some of the articles our esteemed speakers have published recently.

Keynote Speakers

Michael Andreeff, MD Anderson Cancer Center, USA
Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality

Joan Brugge, Harvard Medical School, USA
Deubiquitinases Maintain Protein Homeostasis and Survival of Cancer Cells upon Glutathione Depletion


Iannis Aifantis, NYU School of Medicine, USA
3D Chromosomal Landscapes in Hematopoiesis and Immunity

Mariano Barbacid, National Cancer Research Center, Spain
Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF

Alberto Bardelli, University of Turin & Candiolo Cancer Institute-IRCCS, Italy
Adaptive mutability of colorectal cancers in response to targeted therapies

Caroline Dive, CRUK Manchester Institute, UK
Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse

Patricia Elizalde, IBYME, Argentina
Nuclear ErbB-2: a Novel Therapeutic Target in ErbB-2-Positive Breast Cancer?

Manel Esteller, ICREA, Spain
Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis

William D. Figg, National Cancer Institute/NIH, USA
Antibody–drug conjugates for cancer

Annie Huang, SickKids, Canada
A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain Tumor

Johanna Joyce, UNIL/ CHUV, Switzerland
Tumor-Associated Macrophages Suppress the Cytotoxic Activity of Antimitotic Agents

Calvin Kuo, Stanford University, USA
Organoid Modeling of the Tumor Immune Microenvironment

Anthony Letai, Dana-Farber Cancer Institute, USA
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

Johanna Olweus, University of Oslo, Norway
Induction of neoantigen-reactive T cells from healthy donors

Daniel Peeper, NCI, The Netherlands
Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold

Tannishtha Reya, UCSD, USA
A Multiscale Map of the Stem Cell State in Pancreatic Adenocarcinoma

Andrea Schietinger, MSKCC, USA
TOX is a critical regulator of tumour-specific T cell differentiation

Lillian Siu, Princess Margaret Cancer Center, Canada
Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor–Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors

Erwei Song, Sun Yat-Sen Memorial Hospital, China
Immune Checkpoint Inhibition Overcomes ADCP-Induced Immunosuppression by Macrophages

Karen Vousden, Francis Crick Institute, UK
Dynamic ROS Control by TIGAR Regulates the Initiation and Progression of Pancreatic Cancer

Paul Workman, Institute of Cancer Research, UK
Objective, Quantitative, Data-Driven Assessment of Chemical Probes


Supporting Publications
Premium Sponsor
Cell Mentor
Silver Sponsor
Family Support Awards